These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33865815)

  • 1. Mid-regional pro-atrial natriuretic peptide levels before and after hemodialysis predict long-term prognosis.
    Hasselbalch RB; Kristensen JH; Nielsen TL; Plesner LL; Rydahl C; Schou M; Goetze JP; Bundgaard H; Iversen KK
    Clin Biochem; 2021 Aug; 94():20-26. PubMed ID: 33865815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
    Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-regional pro-atrial natriuretic peptide independently predicts short-term mortality in COVID-19.
    Kaufmann CC; Ahmed A; Kassem M; Freynhofer MK; Jäger B; Aicher G; Equiluz-Bruck S; Spiel AO; Funk GC; Gschwantler M; Fasching P; Wojta J; Huber K
    Eur J Clin Invest; 2021 May; 51(5):e13531. PubMed ID: 33657664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.
    Jensen J; Schou M; Kistorp C; Faber J; Hansen TW; Jensen MT; Andersen HU; Rossing P; Vilsbøll T; Jørgensen PG
    Cardiovasc Diabetol; 2020 Oct; 19(1):180. PubMed ID: 33066783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study.
    Odermatt J; Hersberger L; Bolliger R; Graedel L; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
    Clin Chem Lab Med; 2017 Aug; 55(9):1407-1416. PubMed ID: 28107168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial Assessment of Natriuretic Peptides in Patients Undergoing Interventional Closure of the Left Atrial Appendage.
    Luani B; Rauwolf T; Groscheck T; Tanev I; Herold J; Isermann B; Schmeisser A; Braun-Dullaeus RC
    Heart Lung Circ; 2018 Jul; 27(7):828-834. PubMed ID: 28818408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
    Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M
    Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-regional pro-atrial natriuretic peptide levels in the elderly: clinical and prognostic implications, and comparison to B-type natriuretic peptides.
    Eggers KM; Venge P; Lind L
    Clin Chim Acta; 2013 Apr; 419():62-6. PubMed ID: 23415698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
    Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
    Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.
    Seronde MF; Gayat E; Logeart D; Lassus J; Laribi S; Boukef R; Sibellas F; Launay JM; Manivet P; Sadoune M; Nouira S; Solal AC; Mebazaa A;
    Int J Cardiol; 2013 Oct; 168(4):3404-11. PubMed ID: 23684562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
    J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia.
    Nowak A; Breidthardt T; Christ-Crain M; Bingisser R; Meune C; Tanglay Y; Heinisch C; Reiter M; Drexler B; Arenja N; Twerenbold R; Stolz D; Tamm M; Müller B; Müller C
    Chest; 2012 Apr; 141(4):974-982. PubMed ID: 22135381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.
    Gohar A; Rutten FH; den Ruijter H; Kelder JC; von Haehling S; Anker SD; Möckel M; Hoes AW
    Eur J Heart Fail; 2019 Oct; 21(10):1219-1227. PubMed ID: 31209992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
    Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
    Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.